Examination of the follicular lymphoma international prognostic index (FLIPI) in the national lymphocare study (NLCS): A prospective US patient cohort treated predominantly in community practices Journal Article
| Authors: | Nooka, A. K.; Nabhan, C.; Zhou, X.; Taylor, M. D.; Byrtek, M.; Miller, T. P.; Friedberg, J. W.; Zelenetz, A. D.; Link, B. K.; Cerhan, J. R.; Dillon, H.; Sinha, R.; Shenoy, P. J.; Levy, D.; Dawson, K.; Hirata, J. H.; Flowers, C. R. |
| Article Title: | Examination of the follicular lymphoma international prognostic index (FLIPI) in the national lymphocare study (NLCS): A prospective US patient cohort treated predominantly in community practices |
| Abstract: | Background: Because follicular lymphoma (FL) patients have heterogeneous outcomes, the FL international prognostic index (FLIPI) was developed to risk-stratify patients and to predict survival. However, limited data exist regarding the role of FLIPI in the era of routine first-line rituximab (R) and R-chemotherapy regimens and in the setting of community oncology practices. Patients and Methods: We evaluated the outcome data from the National LymphoCare Study (NLCS), a prospective, observational cohort study, which collects data on patients with FL in the United States (US) community practices. Results: Among 1068 male and 1124 female patients with FLIPI data, most were treated in US community practices (79%); 35% were FLIPI good risk, 30% intermediate risk, and 35% poor risk. FLIPI risk groups were significant predictors of overall survival (OS) and progression-free survival (PFS) for patients who undergo watchful waiting (WW), and those who receive non-R-containing regimens, R-alone, and R-chemotherapy combinations. Conclusions: In the setting of contemporary practice with routine R use, stratifying patients into good, intermediate, and poor FLIPI risk groups predicts distinct outcomes in terms of OS and PFS. FLIPI remains an important prognostic index in the R era and should be used in clinical practices to support discussions about prognosis. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. |
| Keywords: | adult; cancer survival; controlled study; major clinical study; overall survival; cancer localization; cancer risk; drug efficacy; monotherapy; united states; rituximab; cancer staging; antineoplastic agent; prospective study; clinical practice; progression free survival; cohort analysis; patient assessment; prediction; risk assessment; follicular lymphoma; drug use; community care; community practice; cancer prognosis; flipi; nlcs; follicular lymphoma international prognostic index; time to treatment |
| Journal Title: | Annals of Oncology |
| Volume: | 24 |
| Issue: | 2 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2013-02-01 |
| Start Page: | 441 |
| End Page: | 448 |
| Language: | English |
| DOI: | 10.1093/annonc/mds429 |
| PROVIDER: | scopus |
| PUBMED: | 23041589 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 March 2013" - "Art. No.: mds429" - "CODEN: ANONE" - "Source: Scopus" |
